Sunshine Biopharma

Q2 FY2026 EarningsQ2 FY2026 results showed a revenue beat of $9.26M vs. $8.60M expected, although top-line growth declined 1.6% YoY due to terminated distribution agreements. Operating loss of $1.61M was significantly worse than the expected $0.76M, as gross margins compressed to 26.2% from 36.4% YoY. GAAP EPS of -$1.15 beat the consensus of -$1.20, primarily driven by a 203.6% increase in the weighted average share count following substantial equity financing and warrant exercises.